Study of zanubrutinib plus sonrotoclax for high-risk CLL/SLL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with CLL or SLL that needs treatment and has high-risk features (like certain gene changes).
- You have not had any prior treatment for your CLL or SLL.
- You have at least one lymph node that can be measured on a CT scan.
- Your kidneys, liver, and blood cell counts are working well enough.
- You are not pregnant or breastfeeding, and you use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This study tests a two-step approach for people who have just been diagnosed with CLL or SLL and need treatment. It starts with a medicine called zanubrutinib, then adds another drug called sonrotoclax for a set period of time. The goal is to see if this combination can control the disease for a long time and maybe allow people to stop treatment after a while.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
This trial tests a combination of three drugs (sonrotoclax, rituximab, and zanubrutinib) for people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma. The goal is to see if the combination works better than current treatments.
Hear when a new CLL (Chronic Lymphocytic Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.